$RENB
RENOVARO INC.

2022 Q4 Form 10-Q Financial Statement

#000173112223000326 Filed on March 09, 2023

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2022 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.013M $4.557M $3.160M
YoY Change -3.41% 2.02% 52.02%
% of Gross Profit
Research & Development $326.0K $2.605M $1.768M
YoY Change -84.8% -13.33% -85.36%
% of Gross Profit
Depreciation & Amortization $28.84K $28.40K $28.33K
YoY Change -9.32% -10.49% -15.51%
% of Gross Profit
Operating Expenses $4.368M $7.191M $4.956M
YoY Change -31.01% -4.18% -65.06%
Operating Profit -$4.368M -$7.191M
YoY Change -31.01% -4.18%
Interest Expense $92.89K $95.59K $4.630K
YoY Change -209.43% -215.69% -104.96%
% of Operating Profit
Other Income/Expense, Net -$89.88K -$509.1K $7.968M
YoY Change -46.26% -81.97% -358.15%
Pretax Income -$4.458M -$7.700M -$90.24M
YoY Change -32.28% -26.05% 419.69%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.458M -$7.700M -$90.24M
YoY Change -32.28% -26.05% 419.71%
Net Earnings / Revenue
Basic Earnings Per Share -$0.08 -$0.14
Diluted Earnings Per Share -$0.08 -$0.14 -$1.71
COMMON SHARES
Basic Shares Outstanding 55.51M shares 55.10M shares
Diluted Shares Outstanding 55.51M shares 55.10M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.119M $7.972M $9.172M
YoY Change -69.95% -48.16% -55.61%
Cash & Equivalents $4.119M $7.972M $9.172M
Short-Term Investments
Other Short-Term Assets $1.271M $160.6K $393.0K
YoY Change 39.53% 105.65% 68.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.389M $8.133M $9.565M
YoY Change -63.13% -47.38% -54.23%
LONG-TERM ASSETS
Property, Plant & Equipment $555.9K $559.6K $586.5K
YoY Change -71.73% -72.89% -72.79%
Goodwill $11.64M $11.64M $11.64M
YoY Change 0.0%
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $74.33M $74.38M $74.48M
YoY Change 235937.71% 354420.44% 354909.48%
Total Long-Term Assets $74.88M $74.94M $75.07M
YoY Change -55.56% -55.56% -55.5%
TOTAL ASSETS
Total Short-Term Assets $5.389M $8.133M $9.565M
Total Long-Term Assets $74.88M $74.94M $75.07M
Total Assets $80.27M $83.07M $84.63M
YoY Change -56.17% -54.87% -55.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.555M $4.683M $1.402M
YoY Change 2631.77% 754.72% 337.32%
Accrued Expenses $932.6K $1.042M $1.031M
YoY Change 15.44% 57.28% -30.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.726M $1.200M $1.200M
YoY Change -0.03%
Total Short-Term Liabilities $11.29M $7.159M $6.451M
YoY Change 82.07% 491.4% 242.06%
LONG-TERM LIABILITIES
Long-Term Debt $1.200M $4.652M $4.577M
YoY Change 0.0% -20.53% -20.8%
Other Long-Term Liabilities $882.3K $934.9K $166.6K
YoY Change -91.28% -90.68% -97.71%
Total Long-Term Liabilities $2.082M $5.587M $5.563M
YoY Change -81.6% -64.82% -57.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.29M $7.159M $6.451M
Total Long-Term Liabilities $2.082M $5.587M $5.563M
Total Liabilities $13.37M $12.75M $12.01M
YoY Change -23.65% -25.42% -19.6%
SHAREHOLDERS EQUITY
Retained Earnings -$216.5M -$212.0M -$204.3M
YoY Change 124.77%
Common Stock $5.572K $5.552K $5.302K
YoY Change 1.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $66.90M $70.32M $72.62M
YoY Change
Total Liabilities & Shareholders Equity $80.27M $83.07M $84.63M
YoY Change -56.17% -54.87% -55.36%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2022 Q2
OPERATING ACTIVITIES
Net Income -$4.458M -$7.700M -$90.24M
YoY Change -32.28% -26.05% 419.71%
Depreciation, Depletion And Amortization $28.84K $28.40K $28.33K
YoY Change -9.32% -10.49% -15.51%
Cash From Operating Activities -$3.385M -$2.820M -$3.050M
YoY Change -26.74% -46.55% -76.59%
INVESTING ACTIVITIES
Capital Expenditures $23.63K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$23.63K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -466.6K $1.625M 1.070M
YoY Change -115.81% -96.34%
NET CHANGE
Cash From Operating Activities -3.385M -$2.820M -3.050M
Cash From Investing Activities -23.63K 0.000
Cash From Financing Activities -466.6K $1.625M 1.070M
Net Change In Cash -3.875M -$1.200M -1.980M
YoY Change 132.08% -77.28% -112.28%
FREE CASH FLOW
Cash From Operating Activities -$3.385M -$2.820M -$3.050M
Capital Expenditures $23.63K $0.00
Free Cash Flow -$3.408M -$2.820M -$3.050M
YoY Change -26.23% -46.5% -76.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001527728
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
usd
CY2022Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
usd
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q4 enob Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
usd
enob Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
usd
CY2022Q4 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
usd
CY2021Q4 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021Q4 enob Restricted Shares Converted To Shares For Services Rendered Value
RestrictedSharesConvertedToSharesForServicesRenderedValue
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
usd
enob Proceeds From Lpc Equity Agreement
ProceedsFromLpcEquityAgreement
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
enob Shares In Lieu Of Interest On1.2 Million Notes Payable Extension
SharesInLieuOfInterestOn1.2MillionNotesPayableExtension
usd
enob Common Shares Issued For Contingent Earn Out Liability
CommonSharesIssuedForContingentEarnOutLiability
usd
enob Period Changes
PeriodChanges
usd
CY2021Q4 us-gaap Sublease Income
SubleaseIncome
usd
us-gaap Sublease Income
SubleaseIncome
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38758
dei Entity Registrant Name
EntityRegistrantName
Enochian Biosciences Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2559340
dei Entity Address Address Line1
EntityAddressAddressLine1
1927 Paseo Rancho Castillo
dei Entity Address City Or Town
EntityAddressCityOrTown
 Los Angeles
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90032
dei City Area Code
CityAreaCode
(305)
dei Local Phone Number
LocalPhoneNumber
918-1980
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ENOB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55705521 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4118896 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9172142 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1270575 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
392996 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
5389471 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
9565138 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
555916 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
586536 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
42084 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
44268 usd
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
61571000 usd
CY2022Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
61571000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
11640000 usd
CY2022Q2 us-gaap Goodwill
Goodwill
11640000 usd
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
61936 usd
CY2022Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
68635 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1013256 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1157086 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
74328276 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
74480989 usd
CY2022Q4 us-gaap Assets
Assets
80273663 usd
CY2022Q2 us-gaap Assets
Assets
84632663 usd
CY2022Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
4555226 usd
CY2022Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1401867 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
932603 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1031462 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
875415 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
220685 usd
CY2022Q2 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
2343318 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
4726390 usd
CY2022Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1200000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
202370 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
253636 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11292004 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6450968 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1200000 usd
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
4577148 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
882303 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
985699 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2082303 usd
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
5562847 usd
CY2022Q4 us-gaap Liabilities
Liabilities
13374307 usd
CY2022Q2 us-gaap Liabilities
Liabilities
12013815 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55705521 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55705521 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53007082 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53007082 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
5572 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
5302 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
283426764 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
276989179 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216502705 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-204345197 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-30275 usd
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-30436 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
66899356 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
72618848 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80273663 usd
CY2021Q4 enob Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.13
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
84632663 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4013063 usd
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3961764 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8569903 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8379268 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
325959 usd
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2337222 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2931334 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5392658 usd
CY2022Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28844 usd
CY2021Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
31805 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
57245 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
63538 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
4367866 usd
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
6330791 usd
us-gaap Operating Expenses
OperatingExpenses
11558482 usd
us-gaap Operating Expenses
OperatingExpenses
13835464 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-4367866 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-6330791 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11558482 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13835464 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-419182 usd
CY2021Q4 enob Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-167255 usd
enob Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
-2991897 usd
CY2022Q4 us-gaap Interest Expense
InterestExpense
92892 usd
CY2021Q4 us-gaap Interest Expense
InterestExpense
93382 usd
us-gaap Interest Expense
InterestExpense
188477 usd
us-gaap Interest Expense
InterestExpense
183121 usd
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
9 usd
CY2022Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
3010 usd
CY2021Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
8487 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
8633 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
15597 usd
CY2022Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-89882 usd
CY2021Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-252150 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-599026 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3159412 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4457748 usd
CY2021Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6582941 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12157508 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16994876 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
34 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-4457748 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-6582941 usd
us-gaap Net Income Loss
NetIncomeLoss
-12157508 usd
us-gaap Net Income Loss
NetIncomeLoss
-16994910 usd
CY2022Q4 enob Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.08
us-gaap Depreciation And Amortization
DepreciationAndAmortization
63538 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-419182 usd
us-gaap Change In Unrealized Gain Loss On Fair Value Hedging Instruments1
ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
-2991897 usd
enob Non Cash Compensation
NonCashCompensation
1845963 usd
enob Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.22
enob Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.33
CY2022Q4 enob Weighted Average Number Of Shares Of Common Stock Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOfCommonStockOutstandingBasicAndDiluted
55509239 shares
CY2021Q4 enob Weighted Average Number Of Shares Of Common Stock Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOfCommonStockOutstandingBasicAndDiluted
52321982 shares
enob Weighted Average Number Of Shares Of Common Stock Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOfCommonStockOutstandingBasicAndDiluted
55304356 shares
enob Weighted Average Number Of Shares Of Common Stock Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOfCommonStockOutstandingBasicAndDiluted
52270821 shares
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-4457748 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-6582941 usd
us-gaap Net Income Loss
NetIncomeLoss
-12157508 usd
us-gaap Net Income Loss
NetIncomeLoss
-16994910 usd
CY2022Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-7915 usd
CY2021Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
3990 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
-161 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
7983 usd
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4449833 usd
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6586931 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12157347 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17002893 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
72618848 usd
CY2022Q3 enob Stock Issued Pursuant To Warrants Exercised Value
StockIssuedPursuantToWarrantsExercisedValue
1625000 usd
CY2022Q3 enob Shares Issued For Earnout Value
SharesIssuedForEarnoutValue
2762500 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1026008 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-7699760 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7754 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
70324842 usd
CY2022Q4 enob Shares Issued In Lieu Of Interest On1.2 Million Note Payable Extension Value
SharesIssuedInLieuOfInterestOn1.2MillionNotePayableExtensionValue
204392 usd
CY2022Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
819955 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-4457748 usd
CY2022Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7915 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
66899356 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
174662939 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2727975 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-10411969 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3993 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
166974952 usd
CY2021Q4 enob Stock Issued Pursuant To Warrants Exercised Value
StockIssuedPursuantToWarrantsExercisedValue
130000 usd
CY2021Q4 enob Shares Issued Pursuant To Lpc Purchase Agreement Value
SharesIssuedPursuantToLpcPurchaseAgreementValue
3048339 usd
CY2021Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2043292 usd
CY2021Q4 enob Shares Issued For Fully Vested Rsus Value
SharesIssuedForFullyVestedRsusValue
9811 usd
CY2021Q4 us-gaap Profit Loss
ProfitLoss
-6582941 usd
CY2021Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3990 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
165619463 usd
us-gaap Net Income Loss
NetIncomeLoss
-12157508 usd
us-gaap Net Income Loss
NetIncomeLoss
-16994910 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
57245 usd
enob Non Cash Compensation
NonCashCompensation
4771267 usd
enob Amortization Of Discount On Note Payable
AmortizationOfDiscountOnNotePayable
149242 usd
enob Amortization Of Discount On Note Payable
AmortizationOfDiscountOnNotePayable
148548 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-46 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-1640 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-425233 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11812 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3153358 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-153810 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-68554 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-677939 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-18520 usd
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-30004 usd
us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-10832 usd
us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
-5566 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6205145 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9897151 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
23633 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5156 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23633 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5156 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1625000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
130000 usd
enob Repayment Of Finance Agreement
RepaymentOfFinanceAgreement
466625 usd
enob Repayment Of Finance Agreement
RepaymentOfFinanceAgreement
227598 usd
enob Proceeds From Lpc Equity Agreement
ProceedsFromLpcEquityAgreement
3048339 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1158375 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2950741 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17157 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-4937 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5053246 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6956503 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9172142 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20664410 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4118896 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13707907 usd
us-gaap Interest Paid Net
InterestPaidNet
30332 usd
us-gaap Interest Paid Net
InterestPaidNet
36462 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
34 usd
enob Finance Agreement Entered Into In Exchange For Prepaid Assets
FinanceAgreementEnteredIntoInExchangeForPrepaidAssets
1139875 usd
enob Finance Agreement Entered Into In Exchange For Prepaid Assets
FinanceAgreementEnteredIntoInExchangeForPrepaidAssets
666875 usd
enob Shares In Lieu Of Interest On1.2 Million Notes Payable Extension
SharesInLieuOfInterestOn1.2MillionNotesPayableExtension
204392 usd
enob Common Shares Issued For Contingent Earn Out Liability
CommonSharesIssuedForContingentEarnOutLiability
2762500 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216502705 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zvjZNos8RnI2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_860_zjl9jufKMdu3">Reclassification</span> – </b>Certain amounts in the prior period financial statements, have been reclassified to conform to the current presentation. For the three and six months ended December 31, 2021, we reclassified lab expenses of $<span id="xdx_905_eus-gaap--OtherGeneralAndAdministrativeExpense_c20211001__20211231_zi2PCS4yxqLf" title="General and administrative expenses">193,137</span> and $<span id="xdx_904_eus-gaap--OtherGeneralAndAdministrativeExpense_c20210701__20211231_z0eorcm92zCe" title="General and administrative expenses">242,330</span>, respectively from general and administrative expenses to research and development expenses<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> </p>
CY2021Q4 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
193137 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
242330 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_840_eus-gaap--UseOfEstimates_zcUWmuVBaD3d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><b><span id="xdx_867_zdsqJ7UkeTJb">Accounting Estimates</span> </b>– The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated. Significant estimates include the fair value and potential impairment of intangible assets, and fair value of equity instruments issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"> </p>
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
3830530 usd
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
8805495 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
42084 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
44268 usd
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
93253000 usd
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
61571000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
11640000 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
325959 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2931334 usd
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2337222 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5392658 usd
CY2022Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1507 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4833436 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7125894 shares
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
819955 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1845963 usd
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
2043292 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4771267 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2993 usd
CY2021Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3814 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7741 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
44268 usd
enob Period Change
PeriodChange
-2993 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-4457748 usd
us-gaap Net Income Loss
NetIncomeLoss
-12157508 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4118896 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216502705 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
967647 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
944014 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
411731 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
357478 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
555916 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
586536 usd
CY2022Q4 us-gaap Depreciation
Depreciation
27338 usd
us-gaap Depreciation
Depreciation
54253 usd
CY2021Q4 us-gaap Depreciation
Depreciation
27990 usd
us-gaap Depreciation
Depreciation
55796 usd
us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
809 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
42084 usd
CY2022Q2 us-gaap Other Indefinite Lived Intangible Assets
OtherIndefiniteLivedIntangibleAssets
73211000 usd
CY2022Q4 us-gaap Other Indefinite Lived Intangible Assets
OtherIndefiniteLivedIntangibleAssets
73211000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
8883 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
11067 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
11067 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
11067 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
42084 usd
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
93253000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
0 usd
CY2017Q4 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On November 13, 2017, the Company entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”), pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year, and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022,
CY2017Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
70800 usd
CY2018Q2 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
On June 19, 2018, the Company entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, the Company entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease expense for the term of the lease is $20,050.
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y8M1D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0403 pure
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
120002 usd
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
246004 usd
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
253384 usd
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
260985 usd
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
313836 usd
CY2022Q4 enob Less Imputed Interest
LessImputedInterest
109538 usd
CY2022Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1084673 usd
CY2021Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2043292 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4771267 usd
CY2022Q2 us-gaap Lessee Finance Sublease Residual Value Guarantee Description
LesseeFinanceSubleaseResidualValueGuaranteeDescription
On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent is $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and will increase by 3% each year over the term of the sub-lease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022.
CY2022Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
96730 usd
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
84113 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
140660 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
168196 usd
CY2022Q4 us-gaap Sublease Income
SubleaseIncome
53310 usd
us-gaap Sublease Income
SubleaseIncome
106620 usd
CY2022Q4 enob Total Net Lease Expense
TotalNetLeaseExpense
43420 usd
CY2021Q4 enob Total Net Lease Expense
TotalNetLeaseExpense
84113 usd
enob Total Net Lease Expense
TotalNetLeaseExpense
34040 usd
enob Total Net Lease Expense
TotalNetLeaseExpense
168196 usd
CY2022Q4 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
43420 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
34040 usd
CY2021Q4 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
84113 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
168196 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1200000 usd
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1200000 usd
CY2022Q4 enob Prepayment Shares
PrepaymentShares
169020 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
204392 usd
CY2022Q4 us-gaap Prepaid Interest
PrepaidInterest
174090 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
30302 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
24181 usd
CY2022Q4 us-gaap Interest Expense Other
InterestExpenseOther
18272 usd
us-gaap Interest Expense Other
InterestExpenseOther
36453 usd
CY2021Q4 us-gaap Interest Expense Other
InterestExpenseOther
18181 usd
us-gaap Interest Expense Other
InterestExpenseOther
36453 usd
CY2021Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2022-11-30
CY2021Q1 us-gaap Derivative Fixed Interest Rate
DerivativeFixedInterestRate
0.06 pure
CY2021Q1 us-gaap Shares Issued
SharesIssued
74054 shares
CY2021Q1 enob Market Price
MarketPrice
298178 usd
CY2022Q2 us-gaap Shares Issued
SharesIssued
47115 shares
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
299178 usd
CY2022Q4 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
1139875 usd
CY2022Q4 us-gaap Derivative Fixed Interest Rate
DerivativeFixedInterestRate
0.0669 pure
CY2022Q4 enob Monthly Installments
MonthlyInstallments
96220 usd
CY2022Q4 enob Repayment On Finance Agreement
RepaymentOnFinanceAgreement
466625 usd
enob Repayment On Finance Agreement
RepaymentOnFinanceAgreement
466625 usd
CY2021Q4 enob Repayment On Finance Agreement
RepaymentOnFinanceAgreement
227598 usd
enob Repayment On Finance Agreement
RepaymentOnFinanceAgreement
227598 usd
CY2022Q4 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
2782 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
2782 usd
CY2022Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
92892 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
188477 usd
CY2021Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
93382 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
183121 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55705521 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55705521 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53007082 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53007082 shares
CY2020Q3 us-gaap Purchase Obligation
PurchaseObligation
20000000 usd
CY2021Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-08-01
enob Extinguishment Of Contingent Consideration Liability
ExtinguishmentOfContingentConsiderationLiability
419182 usd
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17414 shares
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
819955 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1845963 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4990165 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 usd
CY2019Q4 enob Upfront Payment
UpfrontPayment
10000000 usd
CY2019Q4 enob Payment For Expenditures
PaymentForExpenditures
760000 usd
CY2022Q4 enob Prevention And Treatment Research
PreventionAndTreatmentResearch
0 usd
enob Prevention And Treatment Research
PreventionAndTreatmentResearch
0 usd
CY2021Q4 enob Prevention And Treatment Research
PreventionAndTreatmentResearch
75000 usd
enob Prevention And Treatment Research
PreventionAndTreatmentResearch
150000 usd
CY2021Q3 enob Initial Payment
InitialPayment
600000 usd
CY2021Q3 enob Paid Initial Payment
PaidInitialPayment
600000 usd
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17414 shares
CY2022Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0 shares
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
The Company has a consulting agreement for services of a Senior Medical Advisor for up to $210,000 per year on a part-time basis.
CY2022Q4 us-gaap Related Party Costs
RelatedPartyCosts
0 usd
us-gaap Related Party Costs
RelatedPartyCosts
0 usd
CY2021Q4 us-gaap Related Party Costs
RelatedPartyCosts
718500 usd
us-gaap Related Party Costs
RelatedPartyCosts
3537000 usd

Files In Submission

Name View Source Status
enob-20221231_cal.xml Edgar Link unprocessable
0001731122-23-000326-index-headers.html Edgar Link pending
0001731122-23-000326-index.html Edgar Link pending
0001731122-23-000326.txt Edgar Link pending
0001731122-23-000326-xbrl.zip Edgar Link pending
e4477_10q.htm Edgar Link pending
e4477_ex31-1.htm Edgar Link pending
e4477_ex31-2.htm Edgar Link pending
e4477_ex32-1.htm Edgar Link pending
e4477_ex32-2.htm Edgar Link pending
enob-20221231.xsd Edgar Link pending
e4477_10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
enob-20221231_pre.xml Edgar Link unprocessable
enob-20221231_def.xml Edgar Link unprocessable
enob-20221231_lab.xml Edgar Link unprocessable